{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:43:52Z","timestamp":1791877432363,"version":"4.3.4"},"reference-count":13,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T00:00:00Z","timestamp":1222905600000},"content-version":"vor","delay-in-days":31,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2008,9]]},"abstract":"<jats:p><jats:bold>Abstract:\u2002<\/jats:bold> Topical use of corticosteroids may cause immunosuppression and iatrogenic Cushing\u2019s syndrome via hypothalamic\u2010pituitary\u2010adrenal axis. We report two cases with iatrogenic Cushing\u2019s syndrome with different clinical outcomes due to abuse of same potent topical steroid clobetasol propionate. One of them died because of fatal disseminated cytomegalovirus infection. The other patient recovered completely. Physicians and parents should be informed about the adverse effects of such potent topical corticosteroids and physicians should prescribe less potent agents, especially during infancy.<\/jats:p>","DOI":"10.1111\/j.1525-1470.2008.00735.x","type":"journal-article","created":{"date-parts":[[2008,10,2]],"date-time":"2008-10-02T19:02:43Z","timestamp":1222974163000},"page":"544-547","source":"Crossref","is-referenced-by-count":34,"title":["Two Cases of Cushing\u2019s Syndrome Due to Overuse of Topical Steroid in the Diaper Area<sup>1<\/sup>"],"prefix":"10.1111","volume":"25","author":[{"given":"Serap","family":"Semiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin I\u015f\u0131k","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u015eeniz","family":"Ergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u015fallah","family":"Candemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aziz","family":"Polat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,10,2]]},"reference":[{"key":"e_1_2_4_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.01.010"},{"key":"e_1_2_4_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03833.x"},{"key":"e_1_2_4_4_2","doi-asserted-by":"crossref","first-page":"542","DOI":"10.5694\/j.1326-5377.1971.tb87696.x","article-title":"Temporary Cushing\u2019s syndrome from percutaneous absorption of betamethasone 17\u2010valerate","volume":"1","author":"Keipert JA","year":"1971","journal-title":"Med J Aust"},{"key":"e_1_2_4_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.4.5990.203"},{"key":"e_1_2_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0736-8046.2004.21508.x"},{"key":"e_1_2_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70573-0"},{"key":"e_1_2_4_8_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1999.00773.x"},{"key":"e_1_2_4_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.158.3.294"},{"key":"e_1_2_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-2478(01)00183-3"},{"key":"e_1_2_4_11_2","first-page":"413","article-title":"Glucocorticosteroid action on the immune system: molecular and cellular aspects","volume":"9","author":"Boumpas DT","year":"1991","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_4_12_2","doi-asserted-by":"publisher","DOI":"10.1159\/000087288"},{"key":"e_1_2_4_13_2","unstructured":"WeaverJ.Post marketing safety review\u2014PID D010141. Drugs: topical corticosteroids. FDA Web site. 9 July 2001.http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/03\/briefing\/3999B1_21_Weaver\u2010Memo%2007\u201009\u201001.pdf[accessed on 2 September 2008]."},{"key":"e_1_2_4_14_2","unstructured":"Clotrimazole USP and betamethasone dipropionate USP.Document information page. FDA Web site. 3 October 2003.http:\/\/www.fda.gov\/cder\/foi\/label\/2003\/20010slr005_lotrisone_lbl.pdf[accessed on 2 September 2008]."}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1525-1470.2008.00735.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1525-1470.2008.00735.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T23:00:13Z","timestamp":1697151613000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1525-1470.2008.00735.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":13,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["10.1111\/j.1525-1470.2008.00735.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00735.x","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}